a public good project by the
Synthesis
Company
of California

© 2026

Lon Smith | doi.page

0 works0 citations0 h-index

Lon Smith

South Texas Accelerated Research Therapeutics(US)Start Treatment & Recovery Centers(US)

Publications by Year

Research Areas

Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research

Most-Cited Works

→ Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial(2011)1,042 cited
→ Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors(2015)774 cited
→ The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer(2012)431 cited
→ Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.(1996)352 cited
→ Phase I and pharmacokinetic trial of weekly CPT-11.(1993)303 cited
→ Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study(2003)204 cited

→ A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours(2013)

88 cited

→ Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies(2000)85 cited

→ Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.(2012)81 cited

→ Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors(2014)81 cited